Suicidal Risks in Reports of Long-Term Treatment Trials for Major Depressive Disorder

Affiliations

¹ Department of Psychiatry, Harvard Medical School, Boston, MA (Dr Baldessarini); International Consortium for Psychotic and Mood Disorders Research, McLean Hospital, Belmont, MA (Drs Baldessarini and K Sim); Yong Loo Lin School of Medicine, National University of Singapore (Drs Lau, J Sim, and K Sim); Research Department (Dr K Sim and Ms Sum), and Department of General Psychiatry (Dr K Sim), Institute of Mental Health, Singapore. rbaldessarini@mclean.harvard.edu.
² Department of Psychiatry, Harvard Medical School, Boston, MA (Dr Baldessarini); International Consortium for Psychotic and Mood Disorders Research, McLean Hospital, Belmont, MA (Drs Baldessarini and K Sim); Yong Loo Lin School of Medicine, National University of Singapore (Drs Lau, J Sim, and K Sim); Research Department (Dr K Sim and Ms Sum), and Department of General Psychiatry (Dr K Sim), Institute of Mental Health, Singapore.

Review

Ross J Baldessarini et al. Int J Neuropsychopharmacol. 2015.

. 2015 Sep 13;19(3):pyv107.

doi: 10.1093/ijnp/pyv107.

¹ Department of Psychiatry, Harvard Medical School, Boston, MA (Dr Baldessarini); International Consortium for Psychotic and Mood Disorders Research, McLean Hospital, Belmont, MA (Drs Baldessarini and K Sim); Yong Loo Lin School of Medicine, National University of Singapore (Drs Lau, J Sim, and K Sim); Research Department (Dr K Sim and Ms Sum), and Department of General Psychiatry (Dr K Sim), Institute of Mental Health, Singapore. rbaldessarini@mclean.harvard.edu.
² Department of Psychiatry, Harvard Medical School, Boston, MA (Dr Baldessarini); International Consortium for Psychotic and Mood Disorders Research, McLean Hospital, Belmont, MA (Drs Baldessarini and K Sim); Yong Loo Lin School of Medicine, National University of Singapore (Drs Lau, J Sim, and K Sim); Research Department (Dr K Sim and Ms Sum), and Department of General Psychiatry (Dr K Sim), Institute of Mental Health, Singapore.

No abstract available

Comment in

Suicidal Risks in Report of Reports of Long-Term Treatment Trials for Major Depressive Disorder.
Dardennes R, Al Anbar N, Divac S, Cohen J. Dardennes R, et al. Int J Neuropsychopharmacol. 2017 Mar 1;20(3):279-280. doi: 10.1093/ijnp/pyw084. Int J Neuropsychopharmacol. 2017. PMID: 27655729 Free PMC article. No abstract available.
Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II.
Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Baldessarini RJ, et al. Int J Neuropsychopharmacol. 2017 Mar 1;20(3):281-284. doi: 10.1093/ijnp/pyw092. Int J Neuropsychopharmacol. 2017. PMID: 28003313 Free PMC article. No abstract available.

1. Baldessarini RJ. (2013). Chemotherapy in psychiatry, 3rd edition. New York: Springer Press.
1. Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M. (2007). Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 15:133–145. - PubMed
1. Bostwick JM, Pankratz VS. (2000). Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925–1932. - PubMed
1. Kessler RC, Berglund P, Borges G, Nock M, Wang PS. (2005). Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA 293:2487–2495. - PubMed
1. Nischal A, Tripathi A, Nischal A, Trivedi JK. (2012). Suicide and antidepressants: what current evidence indicates. Mens Sana Monogr 10:33–44. - PMC - PubMed